According to a recent study, the dominant variant of the novel COVID-19 virus – which emerged in patients after the convalescent plasma treatment – undergoes a mutation which might also be existing in the variant first discovered in the UK.
The study also revealed the possibility that the evolution of coronavirus or the SARS-CoV-2 virus might occur in immunocompromised people if drawn out viral replication happens.
As per the published research work in the peer-reviewed journal Nature, “data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy associated with the emergence of viral variants with evidence of reduced susceptibility to neutralising antibodies”.
The released report further added that the study was done on a male patient who had a compromised immune system in the 70s and was infected with the SARS-CoV-2 virus.
Researchers also found that the subject was unsuccessfully treated with antibiotics and steroids of the antivirus drug ‘Remdesivir’ and also after a convalescent plasma therapy during the course of 101 days.
Ravindra Gupta, researcher at Cambridge University in the UK and his team, said that they had collected samples of the virus on 23 occasions during the time of the treatment.
As per the study, the emergence of this coronavirus variant was not due to the failure of the treatment. Whole quoting the vital drawbacks of the research, the researchers said that it was only a case study and the generalisability of the outcome might be restricted.
Gupta and his team, however, expressed their thoughts on findings warrant caution in the usage of the convalescent plasma theapy for the treatment of the novel coronavirus in immunosuppressed patients.